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MPS type Patient no.a Gender Age (years)b Weight (kg)b Mutation(s)c Residual enzyme activityd
IIIA IIIA-2 Female 5 18 R74C/ G90R 0.01
IIIA-4 Female 6 28 nd/nd 0.12
IIIA-5 Male 7 30 R74C / R74C 1.5
IIIA-6 Female 3 22 S66W / S66W 0.15
IIIA-7 Female 7 30 R74C / R74C 0.01
IIIA-8 Female 18 30 R74C / R74C 0.01
IIIB IIIB-2 Male 14 36 E120X/nd 3.0
IIIB-5 Female 9 43 nd/nd 0.01
Table 1. Patients’ characteristics.
a Numbers of patients correspond to those described previously (15). Patients IIIA-2, IIIA-4, IIIA-5, IIIB-2 and IIIB-5 were enrolled also in that study;
b the presented values were measured at baseline; c nd – not determined; d residual activities of enzymes deficient in MPS IIIA and MPS IIIB were 
measured in leukocytes, and were determined as heparan N-sulfatase (MPS IIIA) in nmoles/mg of protein/18 h (controls: 4.1±1.4) or as α-N-aceltyl 
glucosaminidase (MPS IIIB) in nmoles/mg of protein/42 h (controls: 90±34).
Patient
BAE scorea Questionnaires (general score)b
Baseline 1 year 3 years Baseline 1 year 3 years
IIIA-2 14 19 21 –1 +16 +19
IIIA-4 0 4 4 +4 +21 +5
IIIA-5 11 17 19 –10 +22 +23
IIIA-6 25 29 25 0 +13 +8
IIIA-7 38 38 38 –1 +8 +7
IIIA-8 2 4 2 –3 +14 +15
IIIB-2 33 36 32 –4 +6 +13
IIIB-5 27 32 32 –16 +26 +29
Table 2.  Assessment of cognitive functions of patients by using the modified BAE test, and estimation of a generalized score for estimation of 
general and behavioral symptoms in patients.
a For information about calculation of the BAE score, see Appendix; b General score was calculate by summing all answers given by parents to 
18 questions included in the questionnaire (for details see Table 3), giving following weights to particular types of answers: (–2) considerably 
deteriorated, (–1) somewhat deteriorated, (0) no changes, (+1) somewhat improved, (+2) considerably improved.
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Scores given to patients by parentsa
Patient no.
IIIA-2 IIIA-4 IIIA-5 IIIA-6 IIIA-7 IIIB-8 IIIB-2 IIIB-5
Speech performance 0/+1/0 0/+1/0 –1/0/0 0/+1/–1 –1/0/0 0/0/0 0/0/0 –1/+2/+2
Speech understanding 0/+1/0 0/+1/0 –1/+1/+1 0/+2/0 0/+1/+1 0/+1/+1 0/+1/+1 –1/+2/+1
Activity 0/+1/+1 0/+2/+2 –1/+2/+2 0/+2/+1 0/+1/0 –1/0/+1 0/0/+1 0/+1/0
General behavior 0/+1/+1 0/+2/0 –1/+2/+2 0/+1/+1 0/+1/+1 0/+1/+2 0/+1/+1 –1/+2/+2
Sleeping problems 0/+1/+1 0/+1/+2 –1/+2/+2 0/+1/+1 0/0/0 0/+2/+2 –1/+1/+1 –2/+2/+2
Pain 0/0/+1 0/0/0 0/0/0 0/0/+1 0/0/–1 +1/+2/+2 0/0/0 –2/+2/+2
Walking 0/+2/–1 0/+1/–2 0/+2/0 0/+2/+2 0/0/0 –1/0/0 –1/0/+1 –2/+1/0
Hand mobility 0/0/+1 0/+1/–1 –1/+2/+2 0/0/+2 0/0/0 0/0/+1 0/0/+1 0/+1/+2
Joint mobility 0/0/+1 0/+2/–1 –1/+2/0 0/0/+1 0/0/0 0/0/0 0/0/0 –1/+1/+2
Breathing problems (day) 0/+1/+2 +1/+2/0 0/0/0 0/–1/0 0/+2/0 0/0/0 0/0/0 0/0/+2
Breathing problems 
(night) 0/+1/+2 +1/+2/+1 0/+2/+2 0/–1/+1 0/+2/0 0/0/0 0/0/0 –1/+2/+2
Infections –1/+2/+2 +2/+2/+2 0/+1/+2 0/–1/0 0/0/+2 0/0/0 0/+2/+2 –1/+2/+2
Vision 0/0/0 0/0/0 0/0/+2 0/0/0 0/0/+1 0/0/0 –1/0/+2 0/0/0
Hearing 0/0/0 0/+2/0 0/0/+2 0/+2/–1 0/0/0 0/0/0 0/0/0 0/0/+2
Skin 0/+2/+2 0/+1/+1 0/0/0 0/0/0 0/0/+2 0/+2/+2 0/0/0 –1/+2/+2
Hair 0/+2/+2 0/+1/+1 –1/+2/+2 0/+2/–1 0/+1/+1 0/+2/+2 0/0/+1 –1/+2/+2
Dyspeptic symptoms 0/+1/+2 0/+1/+1 –1/+2/+2 0/+2/–1 0/0/0 –1/+2/+1 –1/0/0 –1/+2/+2
Stools 0/0/+2 0/–1/–1 –1/+2/+2 0/+1/+2 0/0/0 –1/+2/+1 0/+1/+2 –1/+2/+2
Tabele 3. Parents’ assessment of patients’ condition.
a The first number (before the first slash sign) is a score for the comparison of changes in a particular child from a year before the onset of the 
treatment to the start of the therapy, the number between slashes is a score for the comparison of changes in a particular child from the onset of 
the treatment to a year after the start of the therapy, and the number after the second slash is a score for the comparison of changes in a particular 
child from the onset of the treatment to 3 years after the start of the therapy. The following score scale was used: considerably deteriorated (–2), 
somewhat deteriorated (–1), no changes (0), somewhat improved (+1), considerably improved (+2).
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